BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21725128)

  • 21. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
    Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
    Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prasugrel as a safe alternative for clopidogrel-associated arthritis.
    Kanadiya MK; Singhal S; Koshal VB
    J Invasive Cardiol; 2011 Jun; 23(6):E137-8. PubMed ID: 21646658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
    Capranzano P; Ferreiro JL; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Apr; 7(4):361-9. PubMed ID: 19379060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimizing of thienopyridine therapy by multiple electrode platelet aggregometry in clopidogrel low responders undergoing PCI.
    Behr T; Kuch B; Behr W; von Scheidt W
    Clin Res Cardiol; 2011 Oct; 100(10):907-14. PubMed ID: 21533581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study).
    Tanzilli G; Greco C; Pelliccia F; Pasceri V; Barillà F; Paravati V; Pannitteri G; Gaudio C; Mangieri E
    Am J Cardiol; 2009 Nov; 104(10):1357-61. PubMed ID: 19892050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
    Orban M; Riegger J; Joner M; Tada T; Okrojek R; Hausleiter J; Kastrati A; Massberg S; Sibbing D
    Platelets; 2012; 23(5):395-8. PubMed ID: 22671583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients.
    Tavassoli N; Voisin S; Carrie D; Lapeyre-Mestre M; Galinier M; Montastruc JL; Pathak A
    Am J Cardiovasc Drugs; 2010; 10(1):29-35. PubMed ID: 20104932
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple antiplatelet therapy for clopidogrel resistance with stent malapposition: a case report.
    Ding FH; Zhang Q; Zhang RY; Hu J; Shen J; Zhao LP; DU R; Zhang X; Shen WF
    Chin Med J (Engl); 2009 Sep; 122(18):2186-8. PubMed ID: 19781309
    [No Abstract]   [Full Text] [Related]  

  • 32. Efficacy of modified dual antiplatelet therapy combined with warfarin following percutaneous coronary intervention with drug-eluting stents.
    Baber U; Akhter M; Kothari S; Sharma SK; Kini A
    J Invasive Cardiol; 2010 Feb; 22(2):80-3. PubMed ID: 20124594
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent.
    Wang ZJ; Zhou YJ; Liu YY; Yu M; Shi DM; Zhao YX; Guo YH; Cheng WJ; Jia de A; Cao Z; Nie B; Ge HL; Yang SW; Yan ZX
    Thromb Res; 2009 May; 124(1):46-51. PubMed ID: 19041120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
    Samoš M; Šimonová R; Kovář F; Duraj L; Fedorová J; Galajda P; Staško J; Fedor M; Kubisz P; Mokáň M
    Am J Emerg Med; 2014 May; 32(5):461-5. PubMed ID: 24560391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
    Sibbing D; Morath T; Braun S; Stegherr J; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2010 Jan; 103(1):151-9. PubMed ID: 20062919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
    Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
    Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug-specific thienopyridine resistance in patient with recurrent coronary stent thrombosis.
    Milicic D; Skoric B; Lovric D
    J Invasive Cardiol; 2009 Aug; 21(8):E157-60. PubMed ID: 19652267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring aspirin resistance, clopidogrel responsiveness, and postprocedural markers of myonecrosis in patients undergoing percutaneous coronary intervention.
    Buch AN; Singh S; Roy P; Javaid A; Smith KA; George CE; Pichard AD; Satler LF; Kent KM; Suddath WO; Waksman R
    Am J Cardiol; 2007 Jun; 99(11):1518-22. PubMed ID: 17531573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis.
    Pinto Slottow TL; Bonello L; Gavini R; Beauzile P; Sushinsky SJ; Scheinowitz M; Kaneshige K; Xue Z; Torguson R; Tantry U; Pichard AD; Satler LF; Suddath WO; Kent K; Gurbel P; Waksman R
    Am J Cardiol; 2009 Aug; 104(4):525-30. PubMed ID: 19660606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.
    Oberhänsli M; Lehner C; Puricel S; Lehmann S; Togni M; Stauffer JC; Baeriswyl G; Goy JJ; Cook S
    Arch Cardiovasc Dis; 2012 Nov; 105(11):587-92. PubMed ID: 23177487
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.